• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Teva launches breath-activated asthma aerosol in U.S.

February 12, 2018 By Sarah Faulkner

Teva's Qvar RediHalerTeva Pharmaceuticals (NYSE:TEVA) has launched its Qvar RediHaler inhalation aerosol in the U.S., marking the first time a breath-actuated inhaled corticosteroid is available for asthma patients as a prophylactic therapy.

In contrast to traditional metered-dose inhalers, Teva’s Qvar RediHaler sends medication into the user’s lungs as they inhale. This feature eliminates the need for hand-breath coordination, according to Teva.

“When it comes to the treatment of asthma, proper inhaler technique remains a critical issue for patients. In fact, nearly 68% of patients do not use their metered dose inhalers well enough to benefit from the prescribed medication, leading to potentially uncontrolled asthma symptoms,” Dr. Warner Carr, of the Allergy and Asthma Associates of Southern California, said in prepared remarks.

“As a physician, it’s often a challenge to know if my patients are using their inhalers correctly once they leave the office. It’s reassuring to see new device technologies come to market, such as the Qvar RediHaler device, which is designed specifically to eliminate the need for hand-breath coordination.”

“Qvar has been an available asthma treatment option for well over a decade, so we are excited by the new technology of Qvar RediHaler that directly addresses an unmet need in the field of asthma management,” Brendan O’Grady, EVP of Teva’s North America commercial business, added. “By merging our breath-actuated inhaler technology with asthma medication, we hope to better serve the needs of the respiratory community and look forward to seeing the adoption of Qvar RediHaler in the coming months.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Teva Pharmaceuticals

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS